Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody

Srilatha Edupuganti(Emory University), Elizabeth Greene(Impact), Nyaradzo Mgodi(University of Zimbabwe), Robert De La Grecca(Infectious Disease Research Institute), Maurine D. Miner(Fred Hutch Cancer Center), Myron S. Cohen(University of North Carolina at Chapel Hill), Carissa Karg(Infectious Disease Research Institute), Allan C. deCamp(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Nidhi Kochar(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Maija Anderson(Fred Hutch Cancer Center), Erika Rudnicki(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Peter L. Anderson(University of Colorado Denver), Margarita M. Gomez Lorenzo(Norwegian Womens Public Health Association), Lawrence Corey(Fred Hutch Cancer Center), India Tindale(Infectious Disease Research Institute), Jonathan Lucas(Family Health International 360), Shelly Karuna(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ian Frank(Norwegian Womens Public Health Association), Pedro Gonzáles(Hospital Nacional Dos de Mayo), John R. Mascola(National Institute of Allergy and Infectious Diseases), Julie E. Ledgerwood(Vaccine Research Institute of San Diego), Peter B. Gilbert(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Magdalena E. Sobieszczyk(Columbia University Irving Medical Center), P. Andrew(Family Health International 360), Gail Broder(Infectious Disease Research Institute), David Burns(Norwegian Womens Public Health Association), Jorge A. Gallardo-Cartagena(National University of San Marcos), John Hural(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
JAIDS Journal of Acquired Immune Deficiency Syndromes
February 25, 2021
Cited by 26


Related Papers